MedTrace Logo

Nicorandil in Atherosclerosis Risk in Patients With Rheumatoid Arthritis

NCT07800351 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-09-02

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the effects of adding nicorandil to conventional Disease-Modifying Antirheumatic Drugs(DMARDs) in treatment of patients with rheumatoid arthritis. The main questions it aims to answer are:

Does adding nicorandil to conventional DMARDs in treatment of patients with rheumatoid arthritis reduce the risk of plaque buildup in arteries (atherosclerosis) ? and What medical problems may participants have when taking nicorandil ?

Participants will:

Take nicorandil added to DMARDs or DMARDs only for 3 months patient will be assessed at baseline and 3 months after for disease activity and risk of plaque formation over vascular wall

Keep a diary of their symptoms and possible side effects

Conditions

Interventions

DRUG

Nicorandil 10 MG Oral scored Tablet

Nicorandil 5 mg oral (half of scored tablet 10 mg) taken twice daily before meals added on csDMARD for 3 months.

DRUG

DMARD maintenance

used as control group

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Salwa El Morsy Abd El Ghanv M Abd El Ghany, MD, PhD · Rheumatology, Rehabilitation and Physical Medicine department -Tanta university

  • Mohamed H Abu-Zaid, MD, PhD · Rheumatology, Rehabilitation and Physical Medicine department -Tanta university

  • Aya M El Shanshory, resident doctor · Rheumatology, Rehabilitation and Physical Medicine department -Tanta university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2027-02-28
Completion
2027-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07800351 on ClinicalTrials.gov